Your browser doesn't support javascript.
loading
Combination therapies induce cancer cell death through the integrated stress response and disturbed pyrimidine metabolism.
Hartleben, Goetz; Schorpp, Kenji; Kwon, Yun; Betz, Barbara; Tsokanos, Foivos-Filippos; Dantes, Zahra; Schäfer, Arlett; Rothenaigner, Ina; Monroy Kuhn, José Manuel; Morigny, Pauline; Mehr, Lisa; Lin, Sean; Seitz, Susanne; Tokarz, Janina; Artati, Anna; Adamsky, Jerzy; Plettenburg, Oliver; Lutter, Dominik; Irmler, Martin; Beckers, Johannes; Reichert, Maximilian; Hadian, Kamyar; Zeigerer, Anja; Herzig, Stephan; Berriel Diaz, Mauricio.
Afiliación
  • Hartleben G; Institute for Diabetes and Cancer, Helmholtz Center Munich, Neuherberg, Germany.
  • Schorpp K; Joint Heidelberg-IDC Translational Diabetes Program, Heidelberg University Hospital, Heidelberg, Germany.
  • Kwon Y; German Center for Diabetes Research (DZD), Neuherberg, Germany.
  • Betz B; Assay Development and Screening Platform, Institute of Molecular Toxicology and Pharmacology, Helmholtz Zentrum München, Neuherberg, Germany.
  • Tsokanos FF; Institute for Diabetes and Cancer, Helmholtz Center Munich, Neuherberg, Germany.
  • Dantes Z; Joint Heidelberg-IDC Translational Diabetes Program, Heidelberg University Hospital, Heidelberg, Germany.
  • Schäfer A; German Center for Diabetes Research (DZD), Neuherberg, Germany.
  • Rothenaigner I; Institute for Diabetes and Cancer, Helmholtz Center Munich, Neuherberg, Germany.
  • Monroy Kuhn JM; Joint Heidelberg-IDC Translational Diabetes Program, Heidelberg University Hospital, Heidelberg, Germany.
  • Morigny P; German Center for Diabetes Research (DZD), Neuherberg, Germany.
  • Mehr L; Institute for Diabetes and Cancer, Helmholtz Center Munich, Neuherberg, Germany.
  • Lin S; Joint Heidelberg-IDC Translational Diabetes Program, Heidelberg University Hospital, Heidelberg, Germany.
  • Seitz S; German Center for Diabetes Research (DZD), Neuherberg, Germany.
  • Tokarz J; Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
  • Artati A; Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
  • Adamsky J; Assay Development and Screening Platform, Institute of Molecular Toxicology and Pharmacology, Helmholtz Zentrum München, Neuherberg, Germany.
  • Plettenburg O; Institute for Diabetes and Obesity, Neuherberg, Germany.
  • Lutter D; Institute for Diabetes and Cancer, Helmholtz Center Munich, Neuherberg, Germany.
  • Irmler M; Joint Heidelberg-IDC Translational Diabetes Program, Heidelberg University Hospital, Heidelberg, Germany.
  • Beckers J; German Center for Diabetes Research (DZD), Neuherberg, Germany.
  • Reichert M; Institute for Diabetes and Cancer, Helmholtz Center Munich, Neuherberg, Germany.
  • Hadian K; Joint Heidelberg-IDC Translational Diabetes Program, Heidelberg University Hospital, Heidelberg, Germany.
  • Zeigerer A; German Center for Diabetes Research (DZD), Neuherberg, Germany.
  • Herzig S; Assay Development and Screening Platform, Institute of Molecular Toxicology and Pharmacology, Helmholtz Zentrum München, Neuherberg, Germany.
  • Berriel Diaz M; Institute for Diabetes and Cancer, Helmholtz Center Munich, Neuherberg, Germany.
EMBO Mol Med ; 13(4): e12461, 2021 04 09.
Article en En | MEDLINE | ID: mdl-33665961
ABSTRACT
By accentuating drug efficacy and impeding resistance mechanisms, combinatorial, multi-agent therapies have emerged as key approaches in the treatment of complex diseases, most notably cancer. Using high-throughput drug screens, we uncovered distinct metabolic vulnerabilities and thereby identified drug combinations synergistically causing a starvation-like lethal catabolic response in tumor cells from different cancer entities. Domperidone, a dopamine receptor antagonist, as well as several tricyclic antidepressants (TCAs), including imipramine, induced cancer cell death in combination with the mitochondrial uncoupler niclosamide ethanolamine (NEN) through activation of the integrated stress response pathway and the catabolic CLEAR network. Using transcriptome and metabolome analyses, we characterized a combinatorial response, mainly driven by the transcription factors CHOP and TFE3, which resulted in cell death through enhanced pyrimidine catabolism as well as reduced pyrimidine synthesis. Remarkably, the drug combinations sensitized human organoid cultures to the standard-of-care chemotherapy paclitaxel. Thus, our combinatorial approach could be clinically implemented into established treatment regimen, which would be further facilitated by the advantages of drug repurposing.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: EMBO Mol Med Asunto de la revista: BIOLOGIA MOLECULAR Año: 2021 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: EMBO Mol Med Asunto de la revista: BIOLOGIA MOLECULAR Año: 2021 Tipo del documento: Article País de afiliación: Alemania